Expert opinion on drug safety
-
Expert Opin Drug Saf · Jan 2017
Review Meta Analysis Comparative StudyRisk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
A previous meta-analysis demonstrated that 3 of the new-generation BCR-ABL tyrosine kinase inhibitors (TKIs) (dasatinib, nilotinib and ponatinib) are associated with an increased risk of vascular occlusive events in patients with Ph+ chronic myeloid leukemia compared with imatinib. This meta-analysis of randomized controlled trials aims at assessing these risks separately. ⋯ Vascular occlusive events associated with new-generation BCR-ABL TKIs are driven by arterial occlusive events.